Slingshot members are tracking this event:
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 25, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fda, Nda, Tenofovir Alafenamide, Taf, Chronic Hepatitis B